Medtronic plc. vs Abbott Laboratories
A head-to-head of Medtronic plc. (MDT) and Abbott Laboratories (ABT) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MDT | ABT |
|---|---|---|
| Market Cap | $106.50B | $175.37B |
| P/E (TTM) | 22.31 | 28.20 |
| Forward P/E | 12.38 | 16.60 |
| P/S | 2.83 | 3.56 |
| P/B | 2.13 | 3.82 |
| EV/EBITDA | 12.19 | 15.88 |
| Dividend Yield | 3.42% | 2.08% |
| Profit Margin | 13.20% | 13.91% |
| Gross Margin | 65.02% | 56.42% |
| Operating Margin | 18.78% | 18.17% |
| Revenue Growth (YoY) | +9.86% | +7.78% |
| FCF Yield | 5.25% | 4.59% |
| Debt / Equity | 55.72 | 64.60 |
| Current Ratio | 2.13 | 1.39 |
Which is better: Medtronic plc. or Abbott Laboratories?
- ✓Larger by market cap: Abbott Laboratories
- ✓Cheaper valuation (lower P/E): Medtronic plc.
- ✓Higher dividend yield: Medtronic plc.
- ✓More profitable (net margin): Abbott Laboratories
- ✓Faster revenue growth: Medtronic plc.
- ✓Higher free-cash-flow yield: Medtronic plc.
Across 13 available metrics, Medtronic plc. leads 12–1.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.